Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Teva's laquinimod has failed to meet its primary Phase III endpoint of reducing annualized relapse rate. This is a blow for Teva and development partner Active Biotech, as the drug was on track to become the next oral disease-modifying therapy available for multiple sclerosis (MS). However, hope remains for the drug's potential in Crohn's disease and lupus, for which Phase II trials are ongoing.
Published By Datamonitor
|
02 Aug 2011 |
|
CommentWire
|
Cubist Pharmaceuticals has granted Teva a non-exclusive license to launch a generic version of its antibiotic Cubicin in the US. The move brings the dispute - which had been running since 2009 - to a close, and eliminates the risk of Cubist losing Cubicin sales in the event of Teva winning the patent litigation.
Published By Datamonitor
|
08 Apr 2011 |
|
CommentWire
|
CF101, an orally-available TNF-alpha antagonist, has shown promising results in a Phase IIa study for the treatment of moderate to severe psoriasis. With current therapies focused on topical agents and biologics, this interesting oral compound has potential benefits for an unmet need in the treatment of psoriasis.
Published By Datamonitor
|
09 Sep 2009 |
|
CommentWire
|
Teva Pharmaceutical has received FDA approval for Azilect as a treatment for Parkinson's disease, both as initial monotherapy in early Parkinson's patients and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease. While this is good news for Teva's second proprietary drug, its true potential may only be realized once long-term neuroprotection trials are completed.
Published By Datamonitor
|
19 May 2006 |
|
CommentWire
|
Teva's biggest selling drug Copaxone has shown increased efficacy in multiple sclerosis in a high-dose phase II trial. This points to the possibility of a revival in Copaxone use, and increased competition for Biogen Idec and Elan's Tysabri if and when it is re-launched.
Published By Datamonitor
|
07 Apr 2006 |
|
CommentWire
|
Teva has agreed to acquire rival generics maker Ivax for $7.4 billion. If the deal goes through, Teva will become the dominant force in the generics market again, pushing Novartis' Sandoz into second place. As the gap between these top two players and the rest of the field opens up, smaller companies may struggle to keep pace and could end up being takeover targets themselves.
Published By Datamonitor
|
26 Jul 2005 |
|
CommentWire
|
DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.
Published By Datamonitor
|
15 Jan 2002 |
|
CommentWire
|
The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.
Published By Datamonitor
|
21 Nov 2001 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.